Last Updated : October 21, 2024
Details
FilesGeneric Name:
Brentuximab vedotin
Project Status:
Active
Therapeutic Area:
Hodgkin lymphoma
Manufacturer:
Seagen Canada Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0371-000
Tumour Type:
Lymphoma
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide in previously untreated high-risk HL in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage Hodgkins Lymphoma.
Submission Type:
Initial
Fee Schedule:
N/A
Indications:
Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide in previously untreated high-risk HL in the pediatric population. Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated patients with advanced stage Hodgkins Lymphoma
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Mar-23 |
|---|---|
| Call for patient/clinician input closed | 02-May-23 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | 18-Apr-24 |
| Submission accepted | 03-May-24 |
| Review initiated | 06-May-24 |
| Expert committee meeting (initial) | 10-Jul-24 |
| Draft recommendation issued to sponsor | 24-Jul-24 |
| Draft recommendation posted for stakeholder feedback | 01-Aug-24 |
| End of feedback period | 16-Aug-24 |
| Final recommendation issued to sponsor and drug plans | 29-Aug-24 |
| Final recommendation posted | 17-Sep-24 |
| CADTH review report(s) posted | - |
Files
Last Updated : October 21, 2024